<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2881">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354143</url>
  </required_header>
  <id_info>
    <org_study_id>R01AG057571</org_study_id>
    <nct_id>NCT03354143</nct_id>
  </id_info>
  <brief_title>Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)</brief_title>
  <acronym>HIPAC</acronym>
  <official_title>Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Health Resources</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michigan State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine if lowering blood pressure using FDA approved&#xD;
      medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta&#xD;
      protein accumulation in older adults. Amyloid beta protein is high in the brain of older&#xD;
      adults with Alzheimer's disease. Hypertension may increase brain amyloid beta protein&#xD;
      accumulation and affect memory and thinking ability in older adults. However, whether&#xD;
      lowering blood pressure reduces brain amyloid beta protein and improves brain function is&#xD;
      inconclusive.&#xD;
&#xD;
      The investigators hypothesize that treating high blood pressure alters brain pulsatility,&#xD;
      which in turn reduces brain amyloid beta protein accumulation and improves brain structure&#xD;
      and function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in intracranial pulsatility</measure>
    <time_frame>Baseline and 12-months</time_frame>
    <description>Changes in intracranial pulsatility will be measured with CINE phase-contrast MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid Amyloid-β and tau</measure>
    <time_frame>Baseline and 12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global and regional brain perfusion via Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline and 12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional brain volume via Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline and 12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional cortical thickness via Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline and 12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain white matter hyperintensity (WMH) via Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline and 12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain white matter microstructural integrity via Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline and 12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain neural network functional connectivity via Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline and 12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH-Toolbox neurocognitive function</measure>
    <time_frame>Baseline, 6-months,12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH PROMIS patient-reported outcome measures of physical health</measure>
    <time_frame>Baseline, 6-months, 12-months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH PROMIS patient-reported outcome measures of mental health</measure>
    <time_frame>Baseline, 6-months, 12-months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive Treatment</intervention_name>
    <description>Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.</description>
    <arm_group_label>Intensive Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 55-79, all races/ethnicities, and both women and men are eligible;&#xD;
&#xD;
          2. Mini-mental state exam (MMSE) &gt; 26 to exclude cognitive impairment or dementia;&#xD;
&#xD;
          3. Healthy normotensive subjects (24-hour ambulatory BP&lt;125/75 mmHg without use of&#xD;
             antihypertensive medication);&#xD;
&#xD;
          4. Patients with hypertension defined as 24-hour SBP ≥130 mmHg , patients on BP&#xD;
             medications are eligible;&#xD;
&#xD;
          5. Patients with hypertension are willing to be randomized into either treatment group&#xD;
             and ability to return to clinic or laboratory for follow-up visits over 12 months;&#xD;
&#xD;
          6. Fluency in English, adequate visual and auditory acuity to allow neuropsychological&#xD;
             testing;&#xD;
&#xD;
          7. Screening laboratory tests and ECG without significant abnormalities that might&#xD;
             interfere with the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of stroke, transient ischemic attack, traumatic brain injury or severe&#xD;
             cerebrovascular disease by clinical diagnosis or past MRI/CT;&#xD;
&#xD;
          2. Diagnosis of AD or other type of dementia and neurodegenerative diseases;&#xD;
&#xD;
          3. Evidence of severe depression or other DSM-V Axis I psychopathology&#xD;
&#xD;
          4. Unstable heart disease based on clinical judgment (heart attack/cardiac arrest,&#xD;
             cardiac bypass procedures within previous 6 months and congestive heart failure),&#xD;
             evidence of atrial fibrillation on ECG, or other severe medical conditions;&#xD;
&#xD;
          5. Chronic kidney diseases with GFR &lt; 40 ml/min;&#xD;
&#xD;
          6. Orthostatic hypotension, defined as standing SBP&lt;100 mmHg;&#xD;
&#xD;
          7. History of significant autoimmune disorders such as systemic lupus erythematosus,&#xD;
             rheumatoid arthritis and polymyalgia rheumatica;&#xD;
&#xD;
          8. History of drug or alcohol abuse within the last 2 years;&#xD;
&#xD;
          9. Diagnosis of uncontrolled diabetes mellitus (fasting blood sugar ≥126 mg/dL or A1C&#xD;
             &gt;7.5%)&#xD;
&#xD;
         10. Obstructive sleep apnea;&#xD;
&#xD;
         11. Regularly smoking cigarette within the past year;&#xD;
&#xD;
         12. Severe obesity with BMI ≥ 45;&#xD;
&#xD;
         13. Participants enrolled in another investigational drug or device study within the past&#xD;
             2 months;&#xD;
&#xD;
         14. Carotid stent or sever stenosis (&gt; 50%);&#xD;
&#xD;
         15. Pacemaker or other medical device of metal that precludes performing MRI;&#xD;
&#xD;
         16. History of B12 deficiency or hypothyroidism (stable treatment for at least 3 months is&#xD;
             allowable);&#xD;
&#xD;
         17. Any conditions judged by the study investigators to be either medically inappropriate,&#xD;
             or risky for participant or likely to have poor study adherence;&#xD;
&#xD;
         18. Claustrophobia;&#xD;
&#xD;
         19. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rong Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center and Texas Health Resources</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wanpen Vongpatanasin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Zhu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2017</study_first_posted>
  <last_update_submitted>August 11, 2022</last_update_submitted>
  <last_update_submitted_qc>August 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Rong Zhang</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Cognitive Function</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared approximately 18-24 months after the primary study publication.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

